Management Team

Steven J. Naber

Chairman of the Board

 

Mr. Naber has been involved with the financing and operations of start-up medical device companies for the past 20 years. From October 1998, he served as the Chief Financial Officer of eyeonics, inc. until its acquisition by Bausch & Lomb in 2008. Subsequent to the acquisition, he held operational and financial roles with Bausch & Lomb Surgical, Vertos Medical, Inc., and Orthalign, Inc. From 1999-2002, while serving as the CFO of eyeonics, Mr. Naber also served as a consultant to four Orange County medical device start-up companies: Intralase went public in 2004 and was subsequently sold to Advanced Medical Optics; SenoRx also went public in 2004 and was acquired by C.R. Bard, Inc.; BioLucent was acquired by Hologix, Inc. in 2006; and Vascular Control Systems was acquired by Johnson & Johnson in 2003.



Prior to joining eyeonics, from 1995 until 1997, Mr. Naber served as Vice President, Finance and Chief Financial Officer of Biopsys Medical, Inc., a publicly-held medical device company which was acquired by Johnson & Johnson. From 1991 to 1995, Mr. Naber served as Vice President, Finance and Chief Financial Officer of Ioptex Research, Inc., an ophthalmic device company which was acquired by Allergan, Inc. From 1984 until 1990, Mr. Naber served as Vice President, Finance and Chief Financial Officer of Gradco Systems, Inc., a publicly-held office technology company. Prior to 1984, Mr. Naber held senior operational and financial positions with Mattel Electronics, Inc, and Kraft, Inc. Mr. Naber received a B.B.A. in Accounting from the University of Iowa.

Dr. Tadashi S. Kaneko, Ph.D.

Chief Financial Officer, Secretary, and Co-Founder

 

Dr. Kaneko is a mechanical engineer, biomedical engineer, and machinist who has worked with Dr. Keyak since April 2000. He has experience designing and fabricating equipment for orthopaedic research and is familiar with the use of bone cement to repair bone with tumors. Dr. Kaneko has 12 peer-reviewed publications and abstracts and recently completed his doctoral study in Biomedical Engineering at the University of California at Irvine. A significant portion of Dr. Kaneko’s doctoral dissertation involved the development and evaluation of a radiation transport modeling method for predicting dose distributions in vertebrae injected with radioactive bone cement.

Dr. Harry. B. Skinner, M.D., Ph.D.

Board Member and Co-Founder

 

Dr. Skinner is a co-inventor of radioactive bone cement and has been a Professor of Orthopaedic Surgery in the University of California system for over 20 years. Dr. Skinner is an orthopaedic surgeon and a materials scientist and has well over 100 peer-reviewed publications. Dr. Skinner has had experience with two start-ups, Norian (manufacturer of an injectable bone substitute that was eventually sold to Synthes, Inc.) and Kyphon (developer of kyphoplasty, sold to Medtronic for $4.2B). He has served as a panel member for the FDA, evaluating various orthopaedic devices. Dr. Skinner brings his knowledge of the orthopaedic market, orthopaedic surgery, materials science, and regulatory issues to Bone-Rad Therapeutics.

Dr. Joyce H. Keyak, Ph.D.

Co-Founder

 

Dr. Keyak is a co-inventor of radioactive bone cement and has been the driving force for R&D of products and procedures related to internal radiation therapy, i.e. “brachytherapy”, for bone. Dr. Keyak secured $760,000 from the Department of Defense Breast Cancer Research Program to develop devices and procedures for combining brachytherapy with a bone-strengthening procedure for the spine, vertebroplasty or kyphoplasty. Dr. Keyak has over 16 years experience as Professor of Radiological Sciences, Orthopaedic Surgery, Biomedical Engineering, and Mechanical and Aerospace Engineering at the University of California at Irvine (UCI). She heads the Bone Biomechanics Laboratory at UCI and is an expert on the structure and mechanics of bone. Dr. Keyak has over 60 peer-reviewed publications.

Dr. Varun Sehgal, Ph.D.

Co-Founder

 

Dr. Sehgal is a medical physicist with experience developing brachytherapy techniques. Dr. Sehgal was responsible for the initial “proof of concept” that demonstrated feasibility of using radioactive bone cement to treat bone. He is an Associate Professor of Radiation Oncology at the University of California at Irvine (UCI), is board certified in Therapeutic Radiological Physics by the American Board of Radiology, and is regularly involved in patient treatment at UCI. He also serves on the Special Brachytherapy Modalities Working Group of the American Association of Physicists in Medicine (AAPM). Dr. Sehgal oversees the radiation aspects of the business, such as product development, dosing, radiation shielding, etc. Dr. Sehgal has 20 publications/presentations at national meetings and symposiums for medical physics and radiation oncology.

Dr. Douglas B. Yim, M.D. FSIR

Medical Advisory Board Member

 

Dr. Yim currently serves as the Chief of Interventional Radiology and Image Guided Therapy at UC Irvine Medical Center, where he is an Associate Clinical Professor of Radiology and Surgery at the School of Medicine.  Prior to joining the University of California in Irvine, he was faculty at Emory University in Atlanta, where his clinical practice and research focused on developing minimally invasive, image guided techniques to treat spinal tumors, spinal fractures and pain.  He sits on several advisory boards of large medical device companies in the area of spine interventions and product design.  He has presented and published numerous abstracts, articles and book chapters.  He is a Fellow of the Society of Interventional Radiology, a member of the North American Spine Society and the American Society of Spine Radiology.  After three years at Emory, Dr. Yim was recruited to his current position at UCI. Though he performs the entire scope of IR, his particular area of interest and research is the development of image guided, minimally invasive oncologic interventions.

Dr. Sean M. Tutton, M.D. FSIR

Medical Advisory Board Member

 

Dr. Tutton is Professor and Director of the Division of Vascular & Interventional Radiology at the Medical College of Wisconsin with 18 years of Vascular and Interventional Radiology experience. He has presented and published numerous abstracts, articles and book chapters, and is a Fellow of the Society of Interventional Radiology and a member of the North American Spine Society.

 

Dr. Tutton received his degree from the UMDNJ-New Jersey School of Medicine and completed his residency and fellowship in Interventional Radiology at the Feinberg School of Medicine, Northwestern University in Chicago, IL. After eight years on the Northwestern University faculty at Evanston Northwestern Healthcare, Dr. Tutton moved to the Medical College of Wisconsin in 2005, and now leads the Division of Vascular & Interventional Radiology. He is a Professor of Radiology, Surgery, and, most recently, Palliative Medicine.

 

Dr. Tutton has a clinical and research interest in the curative and palliative treatments of spine and musculoskeletal cancers and their related complications, namely pain and fractures. He is a funded researcher and has participated in numerous clinical trials, most recently as the international Principle Investigator of a prospective randomized 300-patient trial in the minimally invasive treatment of vertebral fractures, securing FDA approval for a novel augmentation device. Improving the outcomes in cancer patients and relief of pain from vertebral and pelvic fractures through image-guided minimally invasive therapies has been his passion for the last 15 years. 

Gary Mistlin

Member, Board of Directors

 

Mr. Mistlin has been a senior executive in the Medical Device business for over 20 years, with experience in both 

public and private companies. Most recently, Mr. Mistlin was Chief Financial Officer for BioForm Medical, a private 

venture capital backed company which had developed a unique dermal filler, from 2003-2007. Previously, from 1999-

2000, he was Chief Financial Officer for PercuSurge, another private venture backed company, which had developed 

a novel product for the new field of distal protection in interventional cardiology. In 2000, PercuSurge was acquired 

by Medtronic, the world’s largest medical device company. Mr. Mistlin then served as General Manager of Medtronic 

PercuSurge from 2000-2002. From 1987-1999, Mr. Mistlin was Sr. Vice President and Chief Financial Officer of 

Mentor Corporation, a diversified public medical device company selling in the fields of plastic surgery, urology and 

ophthalmology.

 

Mr. Mistlin has an undergraduate degree in Finance from U.C. Berkeley and an MBA from Stanford Graduate School 

of Business. Mr. Mistlin obtained a CMA certification while working in consulting for Ernst & Young.